Last mentioned: Mar 14, 2026
Offering Upsized
The company prices an upsized $550M offering due to strong institutional interest.
ARK Invest Trade
Cathie Wood's ARK Invest buys the dip, increasing its position in CRSP shares.
Debt Offering Announced
CRISPR Therapeutics announces a $350M convertible senior notes offering, causing a stock price dip.
Seeking Alpha's post-earnings quant analysis reveals a stark divide in the healthcare sector, with innovation-driven biopharma stocks significantly outperforming retail pharmacy and managed care. The ratings highlight a shift in investor preference toward high-growth obesity and specialty medicine franchises over traditional defensive value plays.
ARK Invest founder Cathie Wood has increased her stake in CRISPR Therapeutics following a stock price decline triggered by a significant convertible debt offering. The move underscores Wood's long-term conviction in the gene-editing sector despite short-term market volatility and capital-raising pressures.
ARK Invest, led by Cathie Wood, has significantly increased its position in CRISPR Therapeutics (CRSP), signaling continued high conviction in the gene-editing pioneer despite recent market fluctuations. This move highlights Wood's strategy of doubling down on disruptive genomic technologies during periods of valuation compression.
While gene therapies offer curative potential for rare and genetic diseases, prohibitive costs and geographic centralization create a significant access gap. This briefing examines the systemic barriers preventing eligible patients from receiving these life-altering treatments.
While gene therapies offer unprecedented curative potential for rare and chronic diseases, high costs and logistical hurdles are creating a significant access gap in the U.S. healthcare system. This briefing examines the systemic challenges preventing widespread adoption and the emerging financial models designed to bridge the divide.
Grünenthal has initiated clinical development for its proprietary NaV 1.8 inhibitor, a highly selective non-opioid analgesic candidate. This milestone positions the German pain specialist as a key contender in the race to develop potent, non-addictive treatments for acute and chronic pain.
Grünenthal Group has initiated clinical development for its proprietary NaV 1.8 inhibitor, a major step toward providing a non-opioid alternative for pain management. This move positions the German pain specialist as a key competitor in the high-growth peripheral sodium channel inhibitor market.